Research compounds
Thymogen
Glu-Trp, thymogen dipeptide
Thymogen is a synthetic dipeptide (glutamyl-tryptophan) derived from thymic peptide research in Russia, marketed as an immunomodulator. It is not approved by the FDA or EMA.
Also known as: Glu-Trp, EW peptide
- Status
- Thymogen is a research compound and not approved by the FDA for human use.
- Evidence
- Anecdotal. Mostly community reports; there is no controlled human data.
- Half-life
- Not established; expected to be extremely short.
- How it's taken
- Intranasal or injection in non-clinical use
- Mechanism
- Immune modulation
- Pathways
- Thymic Immune
How Thymogen works
Thymogen is proposed to act on T-lymphocyte differentiation and on regulation of immune cell populations, in the same conceptual family as thymosin alpha-1 and thymopentin. As the shortest of these peptides, its specificity is correspondingly harder to explain mechanistically, and the proposed mode of action has not been characterised to Western standards.
What research has looked at
- It sits within a genuine research tradition — thymic peptides including thymosin alpha-1 have real immunological activity.
- A dipeptide is inexpensive and simple to synthesise with high purity.
- It has been used clinically in Russia for decades, giving a long uncontrolled tolerability record.
Evidence level: Anecdotal. Mostly community reports; there is no controlled human data. These are areas studied or reported, not promised effects.
Reported side effects and risks
- The evidence base is Russian-language and has not been replicated to Western regulatory standards. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- A dipeptide this short has limited capacity for the receptor specificity that its claimed effects would require, and this tension is not resolved in the literature.
- Immunomodulation without a defined target carries theoretical autoimmune risk that has not been characterised.
- Long-term safety in humans is unstudied.
Sources
- PubMed research on thymogen glutamyl-tryptophan immunomodulator · NIH · National Library of Medicine
- DrugBank record for thymogen · DrugBank
- Active clinical trials for thymogen · U.S. National Library of Medicine
Track Thymogen in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Thymogen FAQ
What is Thymogen?
Thymogen is a synthetic dipeptide (glutamyl-tryptophan) derived from thymic peptide research in Russia, marketed as an immunomodulator. It is not approved by the FDA or EMA.
How does Thymogen work?
Thymogen is proposed to act on T-lymphocyte differentiation and on regulation of immune cell populations, in the same conceptual family as thymosin alpha-1 and thymopentin. As the shortest of these peptides, its specificity is correspondingly harder to explain mechanistically, and the proposed mode of action has not been characterised to Western standards.
Is Thymogen FDA approved?
No. Thymogen is a research compound and not approved by the FDA for human use. Evidence level: anecdotal. Mostly community reports; there is no controlled human data.
How is Thymogen taken?
Intranasal or injection in non-clinical use.
What side effects have been reported with Thymogen?
Reported in the sources: The evidence base is Russian-language and has not been replicated to Western regulatory standards. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; A dipeptide this short has limited capacity for the receptor specificity that its claimed effects would require, and this tension is not resolved in the literature; Immunomodulation without a defined target carries theoretical autoimmune risk that has not been characterised; Long-term safety in humans is unstudied.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.